Mathian et al. uncovered its potency to induce polyclonal antibodies neutralising all 13 subtypes of human IFN-α in human IFN-α transgenic mice, without affecting IFN-β or IFN-γ.69,71 Results from a multicentre, phase I/IIa staggered dose-escalation trial in adult SLE patients immunised with IFN-K, proved its efficacy on developing anti-IFNα antibodies. This evidence concerns the gene IFNA2 and systemic lupus erythematosus.